STI Stock Trade Intelligence
SLD

Saluda Medical, Inc

Health Care · ASX:SLD
$0.4100
0.00%
Market cap
$103M
Turnover
$82,811
Last price
$0.4100
Day change
0.00%
Announcements
8
Range, past year
Open 1.500 · Low 0.360 · Now 0.410 · High 1.520
Open SLD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

SLD momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-09-28.
Momentum quality
20/100
Wyckoff phase
Accumulation53d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+0.0%
1 Month
-14.6%
RSI
42
Avg daily range
7.7%

Saluda Medical, Inc scores 20 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 53 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -40.0%
  • High volatility (ATR 7.7%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
SLD appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

SLD announcements

Recent price-sensitive releases.
  • 2026-09-07 CEO Transition CEO/Managing Director - Appointment Resignation
  • 2026-08-28 FY26 Results Presentation Company Presentation | Preliminary Final Report
  • 2026-08-28 FY26 Full Year Results Web Cast | Preliminary Final Report
  • 2026-08-28 Preliminary Final Report Preliminary Final Report
  • 2026-07-29 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Web Cast | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-06-30 SLD Receives FDA Approval for CAP24 Surgical Paddle Lead
  • 2026-04-30 Quarterly Activities/Appendix 4C Cash Flow Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.